Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of “Buy” by Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has earned a consensus recommendation of “Buy” from the eight research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $69.5714.

MNPR has been the subject of a number of research analyst reports. Oppenheimer initiated coverage on Monopar Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $77.00 target price for the company. Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Monopar Therapeutics in a report on Wednesday, August 13th. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. HC Wainwright started coverage on Monopar Therapeutics in a report on Tuesday, August 26th. They issued a “buy” rating and a $70.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $74.00 target price on shares of Monopar Therapeutics in a report on Wednesday, August 27th.

Insider Activity

In other news, CEO Chandler Robinson sold 16,800 shares of the company’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the chief executive officer owned 73,472 shares in the company, valued at $2,938,880. This represents a 18.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher M. Starr sold 16,800 shares of the company’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the transaction, the director owned 5,173 shares in the company, valued at $206,920. This represents a 76.46% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,504 shares of company stock worth $1,700,160 in the last 90 days. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently made changes to their positions in the business. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics in the second quarter worth approximately $34,000. AlphaQuest LLC acquired a new position in Monopar Therapeutics in the first quarter worth approximately $44,000. JPMorgan Chase & Co. increased its holdings in Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Monopar Therapeutics in the second quarter worth approximately $80,000. Finally, New York State Common Retirement Fund acquired a new position in Monopar Therapeutics in the second quarter worth approximately $104,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Trading Up 13.8%

NASDAQ MNPR opened at $44.21 on Friday. The stock’s 50-day moving average price is $38.33 and its two-hundred day moving average price is $36.65. The company has a market cap of $272.78 million, a PE ratio of -13.28 and a beta of 1.20. Monopar Therapeutics has a 1 year low of $2.29 and a 1 year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.12. Research analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.